Aman Kamasani is an independent researcher focused on emerging health technologies and regulatory strategy. His work is partially inspired by his story with his health. His work examines photobiomodulation science and how FDA device classification influences commercialization and patient trust. He has conducted research at Daylight Computer Co.
For consumers and clinicians the difference between “FDA-cleared,” “FDA-registered,” and general wellness products is not always obvious. Clear communication about intended use and supporting evidence is essential for maintaining trust.